La maladie de Parkinson en France (serveur d'exploration) - Exploration (Accueil)

Index « Keywords » - entrée « Piribedil »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Piperidines (therapeutic use) < Piribedil < Piribedil (administration & dosage)  Facettes :

List of bibliographic references indexed by Piribedil

Number of relevant bibliographic references: 17.
Ident.Authors (with country if any)Title
000F56 (2013) Stéphane Thobois [France] ; Eugénie Lhommee [France] ; Hélène Klinger [France] ; Claire Ardouin [France] ; Emmanuelle Schmitt [France] ; Amélie Bichon [France] ; Andrea Kistner [France] ; Anna Castrioto [France] ; JING XIE [France] ; Valerie Fraix [France] ; Pierre Pelissier [France] ; Stephan Chabardes [France] ; Patrick Mertens [France] ; Jean-Louis Quesada [France] ; Jean-Luc Bosson [France] ; Pierre Pollak [France] ; Emmanuel Broussolle [France] ; Paul Krack [France]Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil
001775 (2011) P. Cesaro [France]Maladie de Parkinson : les enjeux du traitement : MALADIE DE PARKINSON : PEUT-ON EN MODIFIER LE COURS EVOLUTIF ?
001B60 (2010) Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
002416 (2008) A. Marighetto ; S. Valerio [France] ; Jn Philippin [France] ; V. Bertaina-Anglade [France] ; C. Drieu La Rochelle [France] ; R. Jaffard [France] ; P. Morain [France]Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents
002997 (2006) Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees [Royaume-Uni]Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
002A87 (2006) Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]The parkinson-control study : A 1-year randomized, double- blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in parkinson's disease
002A95 (2006) Stéphane Thobois [France]Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease : A review of the literature
002C67 (2005) Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
003144 (2003) Marc Ziegler [France] ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study
003346 (2002) Lance A. Smith [Royaume-Uni] ; Banu C. Tel [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Matthew J. Hansard [Royaume-Uni] ; Rogelio Braceras [Royaume-Uni] ; Céline Bonhomme [France] ; Claire Chezaubernard [France] ; Susanna Del Signore [France] ; Sarah Rose [Royaume-Uni] ; Peter Jenner [Royaume-Uni]Repeated administration of piribedil induces less dyskinesia than L‐dopa in MPTP‐treated common marmosets: A behavioural and biochemical investigation
003418 (2002) Anne-Marie Bonnet [France]Récepteurs α2-adrénergiques et maladie de Parkinson
003536 (2002) C. Lebrun-Frenay [France] ; M. Borg [France]Choosing the right dopamine agonist for patients with Parkinson's disease
003895 (2000) Jj Ferreira [France, Portugal] ; M. Galitzky [France] ; Jl Montastruc [France] ; O. Rascol [France]Sleep attacks and Parkinson's disease treatment
003B54 (2000) L. A. Smith [Royaume-Uni] ; M. G. Jackson [Royaume-Uni] ; C. Bonhomme [France] ; C. Chezaubernard [France] ; K. B. Pearce [Royaume-Uni] ; P. Jenner [Royaume-Uni]Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset
003E49 (1999) Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France]A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease
003E76 (1999) M. Ziegler [France] ; P. Rondot [France]Activité du piribédil dans la maladie de Parkinson : Etude multicentrique
004830 (1995) Blandine Jardon [France] ; Nicole Bonaventure [France]Different effects of dopamine and Piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i -k "Piribedil" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/KwdEn.i  \
                -Sk "Piribedil" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Piribedil
}}

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024